EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F62157124%3A16370%2F19%3A43878068" target="_blank" >RIV/62157124:16370/19:43878068 - isvavai.cz</a>
Výsledek na webu
—
DOI - Digital Object Identifier
—

Jazyk výsledku
angličtina
Název v původním jazyce
EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS
Popis výsledku v původním jazyce
The ADMYRA study was designed to compare the efficacy of biosimilar adalimumab and reference adalimumab for 24 weeks of treatment and to evaluate the long-term efficacy, safety and immunogenicity status by week 48. The study also looked at efficacy, safety and immunogenicity after switching from reference adalimumab to biosimilar adalimumab at week 24 to week 48.
Název v anglickém jazyce
EFFICACY, SAFETY, AND IMMUNOGENICITY RESULTS OF THE SWITCH FROM REFERENCE ADALIMUMAB TO SANDOZ BIOSIMILAR ADALIMUMAB (GP2017, SDZ-ADL) FROM ADMYRA PHASE 3 STUDY IN PATIENTS WITH MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS
Popis výsledku anglicky
The ADMYRA study was designed to compare the efficacy of biosimilar adalimumab and reference adalimumab for 24 weeks of treatment and to evaluate the long-term efficacy, safety and immunogenicity status by week 48. The study also looked at efficacy, safety and immunogenicity after switching from reference adalimumab to biosimilar adalimumab at week 24 to week 48.

Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění
2019
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)